These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33965254)

  • 1. Enterotoxigenic Escherichia coli (ETEC) vaccines: Priority activities to enable product development, licensure, and global access.
    Khalil I; Walker R; Porter CK; Muhib F; Chilengi R; Cravioto A; Guerrant R; Svennerholm AM; Qadri F; Baqar S; Kosek M; Kang G; Lanata C; Armah G; Wierzba T; Hasso-Agopsowicz M; Giersing B; Louis Bourgeois A
    Vaccine; 2021 Jul; 39(31):4266-4277. PubMed ID: 33965254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.
    Hosangadi D; Smith PG; Kaslow DC; Giersing BK;
    Vaccine; 2019 Nov; 37(50):7381-7390. PubMed ID: 29352598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine value profile for enterotoxigenic Escherichia coli (ETEC).
    Khalil I; Anderson JD; Bagamian KH; Baqar S; Giersing B; Hausdorff WP; Marshall C; Porter CK; Walker RI; Bourgeois AL
    Vaccine; 2023 Nov; 41 Suppl 2():S95-S113. PubMed ID: 37951695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of vaccine research and development for enterotoxigenic Escherichia coli.
    Bourgeois AL; Wierzba TF; Walker RI
    Vaccine; 2016 Jun; 34(26):2880-2886. PubMed ID: 26988259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference.
    Walker RI; Wierzba TF; Mani S; Bourgeois AL
    Vaccine; 2017 Dec; 35(49 Pt A):6775-6782. PubMed ID: 28987444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The way forward for ETEC controlled human infection models (CHIMs).
    Hanevik K; Chen WH; Talaat KR; Porter C; Bourgeois L
    Vaccine; 2019 Aug; 37(34):4794-4799. PubMed ID: 30709728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.
    Seo H; Garcia C; Ruan X; Duan Q; Sack DA; Zhang W
    Infect Immun; 2021 Jun; 89(7):e0010621. PubMed ID: 33875477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children.
    Walker RI
    Vaccine; 2015 Feb; 33(8):954-65. PubMed ID: 25482842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis.
    Anderson JD; Bagamian KH; Muhib F; Amaya MP; Laytner LA; Wierzba T; Rheingans R
    Lancet Glob Health; 2019 Mar; 7(3):e321-e330. PubMed ID: 30784633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans.
    Zhang W; Sack DA
    Expert Rev Vaccines; 2012 Jun; 11(6):677-94. PubMed ID: 22873126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference.
    Barry E; Cassels F; Riddle M; Walker R; Wierzba T
    Vaccine; 2019 Aug; 37(34):4768-4774. PubMed ID: 31358236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.
    Khalil IA; Troeger C; Blacker BF; Rao PC; Brown A; Atherly DE; Brewer TG; Engmann CM; Houpt ER; Kang G; Kotloff KL; Levine MM; Luby SP; MacLennan CA; Pan WK; Pavlinac PB; Platts-Mills JA; Qadri F; Riddle MS; Ryan ET; Shoultz DA; Steele AD; Walson JL; Sanders JW; Mokdad AH; Murray CJL; Hay SI; Reiner RC
    Lancet Infect Dis; 2018 Nov; 18(11):1229-1240. PubMed ID: 30266330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in oral enterotoxigenic Escherichia coli vaccines.
    Svennerholm AM; Lundgren A
    Curr Opin Immunol; 2023 Oct; 84():102372. PubMed ID: 37523966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.
    Zhang W; Sack DA
    Clin Vaccine Immunol; 2015 Sep; 22(9):983-91. PubMed ID: 26135975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
    Baqar S; Bonavia A; Louis Bourgeois A; Campo JJ; Clifford A; Hanevik K; Hasso-Agopsowicz M; Hausdorff W; Kaminski R; MacLennan CA; Mantis N; Martin LB; Omore R; Pasetti M; Pavlinac P; Phalipon A; Poly F; Porter C; Ramasamy MN; Rogawski McQuade ET; Sztein MB; Walker R
    Vaccine; 2024 Mar; 42(7):1445-1453. PubMed ID: 38036392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design.
    Amcheslavsky A; Wallace AL; Ejemel M; Li Q; McMahon CT; Stoppato M; Giuntini S; Schiller ZA; Pondish JR; Toomey JR; Schneider RM; Meisinger J; Heukers R; Kruse AC; Barry EM; Pierce BG; Klempner MS; Cavacini LA; Wang Y
    Sci Rep; 2021 Feb; 11(1):2751. PubMed ID: 33531570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens.
    Hasso-Agopsowicz M; Lopman BA; Lanata CF; Rogawski McQuade ET; Kang G; Prudden HJ; Khalil I; Platts-Mills JA; Kotloff K; Jit M; Riddle MS; Pavlinac PB; Luz PM; Pitzer VE; Breiman RF; Giersing BK
    Vaccine; 2021 Dec; 39(52):7521-7525. PubMed ID: 34838322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of enterotoxigenic Escherichia coli genomics for vaccine development.
    Sjöling Å; von Mentzer A; Svennerholm AM
    Expert Rev Vaccines; 2015 Apr; 14(4):551-60. PubMed ID: 25540974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations.
    Banerjee S; Barry EM; Baqar S; Louis Bourgeois A; Campo JJ; Choy RKM; Chakraborty S; Clifford A; Deal C; Estrada M; Fleckenstein J; Hasso-Agopsowicz M; Hausdorff W; Khalil I; Maier N; Mubanga C; Platts-Mills JA; Porter C; Qadri F; Simuyandi M; Walker R; White JA
    Vaccine; 2024 Mar; 42(7):1454-1460. PubMed ID: 38030421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016.
    Wierzba TF; Bourgis A;
    Vaccine; 2017 Jan; 35(4):503-507. PubMed ID: 28034476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.